Breaking News Instant updates and real-time market news.

CL

Colgate-Palmolive

$73.38

0.04 (0.05%)

, JNJ

Johnson & Johnson

$141.68

1.88 (1.34%)

14:04
06/12/19
06/12
14:04
06/12/19
14:04

Colgate-Palmolive, J&J lose jury verdict in talc case, Bloomberg reports

A jury ruled in favor of a woman who blamed her rare cancer on Johnson & Johnson (JNJ) and Colgate's (CL) talc powder products, Bloomberg said.

CL

Colgate-Palmolive

$73.38

0.04 (0.05%)

JNJ

Johnson & Johnson

$141.68

1.88 (1.34%)

  • 12

    Jun

  • 17

    Jun

  • 16

    Jul

  • 26

    Jul

CL Colgate-Palmolive
$73.38

0.04 (0.05%)

04/29/19
JPMS
04/29/19
UPGRADE
Target $70
JPMS
Neutral
JPMorgan upgrades Colgate-Palmolive to Neutral on improved sales growth
JPMorgan analyst Andrea Teixeira upgraded Colgate-Palmolive to Neutral from Underweight and raised her price target for the shares to $70 from $62. The company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S., Teixeira tells investors in a research note. For the first time in two years, Colgate-Palmolive delivered both volume and pricing growth when reporting quarterly results on Friday, says the analyst. She notes that while the company's global market share losses on a year-over-year basis are still lingering, its market share has been more stable sequentially.
04/29/19
JEFF
04/29/19
NO CHANGE
Target $73
JEFF
Hold
Colgate-Palmolive price target raised to $73 from $61 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Colgate-Palmolive to $73 from $61 following the company's "solid" Q1 results. While a recovery in China will take time, Colgate-Palmolive is "importantly seeing progress" across key markets, including the U.S. and Latin America, and the Colgate Total relaunch is progressing in-line with expectations, Grundy tells investors in a research note. He views the company's sales recovery as "encouraging," but thinks the stock's current valuation limits upside potential. As such, he keeps a Hold rating on Colgate-Palmolive.
04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/11/19
ARGS
06/11/19
NO CHANGE
Target $82
ARGS
Buy
Colgate-Palmolive price target raised to $82 from $72 at Argus
Argus analyst Chris Graja raised his price target on Colgate-Palmolive to $82 and kept his Buy rating. The analyst cites the company's 2.4% dividend yield exceeding the 10-year Treasury note payout and expects that dividend to continue to increase. Graja also points to Colgate-Palmolive's accelerating organic sales growth in Q1 to 3% from 2% in Q4 driven by the management's more aggressive advertising initiatives, greater e-commerce product availability, and the company's high financial strength rating relative to his coverage universe.
JNJ Johnson & Johnson
$141.68

1.88 (1.34%)

05/22/19
WELS
05/22/19
NO CHANGE
WELS
Wells Fargo says start of opioid trial won't be positive for Teva shares
Wells Fargo analyst David Maris noted that the nation's first major opioid case, brought against Teva (TEVA) and Johnson & Johnson (JNJ) in Oklahoma, will begin on May 28 and that the entire trial will be webcast. He thinks that the trial start and the opening webcast statements "will not be positive for Teva shares," adding that he suspects the outcome of this suit will be extrapolated to the Multi-District Litigation coming this fall. Maris keeps a Market Perform rating on Teva shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $163
GSCO
Buy
Johnson & Johnson initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Johnson & Johnson with a Buy rating and $163 price target. J&J's diversified portfolio is a potential strength as it results in the company having the lowest exposure to Medicare/Medicaid within the group, Flynn tells investors in a research note. As a result, he thinks the stock will be less impacted by potential drug pricing headlines/policy proposals ahead of the 2020 presidential election.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
Outperform
Johnson & Johnson concerns over opioid case seem 'overblown,' says Wells Fargo
As the first state opioid trial begins in Oklahoma, Wells Fargo analyst Larry Biegelsen continues to believe that litigation will be manageable for Johnson & Johnson given its size and resources. The analyst notes that it appears the company's pain products - Duragesic patch and Nucynta/ER - accounted for less than 1% of the Oklahoma Medicaid opioid prescriptions from 1996-2017, while the company's slides also show data that fentanyl and tapentadol have lower abuse rates and diversion rates versus oxycodone and hydrocodone. Overall, Biegelsen believes concerns over the Oklahoma opioid case "may be overblown." The analyst has an Outperform rating on the shares.
05/30/19
COWN
05/30/19
NO CHANGE
Target $155
COWN
Outperform
Johnson & Johnson weakness may be overdone, says Cowen
Cowen analyst Joshua Jennings noted the State of Oklahoma is claiming Janssen Pharmaceuticals helped fuel the US opioid crisis which then caused volatility in Johnson & Johnson (JNJ) shares. While JNJ maintains its involvement was limited, the analyst says it is challenging to estimate the potential liability. His analysis however suggests, the stock's pullback is overdone. Jennings maintained his Outperform rating and $155 price target on Johnson & Johnson shares.

TODAY'S FREE FLY STORIES

MOS

Mosaic

$24.23

0.8 (3.41%)

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Options
Mosaic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Conference/Events
William Blair financial services/insurance analyst to hold a luncheon »

Financial…

CLXT

Calyxt

$12.42

-0.13 (-1.04%)

12:25
06/25/19
06/25
12:25
06/25/19
12:25
Conference/Events
Calyxt to host investor & analyst day »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Conference/Events
Morgan Stanley energy analysts to hold an analyst/industry conference call »

Analysts discuss PJM…

JPM

JPMorgan

$108.71

0.05 (0.05%)

, BAC

Bank of America

$27.67

-0.31 (-1.11%)

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Periodicals
JPMorgan CEO says 'going right at' BofA in branch expansion, Bloomberg says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$108.71

0.05 (0.05%)

BAC

Bank of America

$27.67

-0.31 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

12:19
06/25/19
06/25
12:19
06/25/19
12:19
Hot Stocks
Mitsubishi Motors North America relocating U.S. headquarters to Tennessee »

Mitsubishi Motors North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/25/19
06/25
12:17
06/25/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/25/19
06/25
12:16
06/25/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$16.87

-0.155 (-0.91%)

12:15
06/25/19
06/25
12:15
06/25/19
12:15
Options
STMicroelectronics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMC

UMC

$2.18

0.03 (1.40%)

12:14
06/25/19
06/25
12:14
06/25/19
12:14
Upgrade
UMC rating change  »

UMC upgraded two notches…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

12:10
06/25/19
06/25
12:10
06/25/19
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AGN

Allergan

$164.20

34.55 (26.65%)

, ABBV

AbbVie

$66.78

-11.63 (-14.83%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have slid in…

AGN

Allergan

$164.20

34.55 (26.65%)

ABBV

AbbVie

$66.78

-11.63 (-14.83%)

TMUS

T-Mobile

$74.93

-0.61 (-0.81%)

S

Sprint

$6.86

(0.00%)

DISH

Dish

$37.93

-0.66 (-1.71%)

LEN

Lennar

$48.75

-2.66 (-5.17%)

PYX

Pyxus

$16.70

3.28 (24.44%)

GRUB

GrubHub

$75.31

3.26 (4.52%)

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

BHF

Brighthouse Financial

$32.74

-5.36 (-14.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 09

    Jul

  • 16

    Sep

DLTR

Dollar Tree

$109.86

-2.86 (-2.54%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
Hot Stocks
Dollar Tree director Thomas Saunders sells over $1.6M in company shares »

Dollar Tree director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$13.72

-0.2 (-1.44%)

12:05
06/25/19
06/25
12:05
06/25/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

12:02
06/25/19
06/25
12:02
06/25/19
12:02
Recommendations
Aldeyra analyst commentary at Stifel »

Stifel says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UNH

UnitedHealth

$249.06

-0.59 (-0.24%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Periodicals
UnitedHealth buys PatientsLikeMe after scrutiny over Chinese investor, CNBC says »

According to a story out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

RGS

Regis

$16.62

-1.15 (-6.47%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Regis falls -6.4% »

Regis is down -6.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$14.36

-1.02 (-6.63%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
EQT Corporation falls -6.6% »

EQT Corporation is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ABBV

AbbVie

$66.64

-11.77 (-15.01%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
AbbVie falls -15.1% »

AbbVie is down -15.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 16

    Sep

USNA

Usana

$78.92

6.515 (9.00%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Usana rises 8.6% »

Usana is up 8.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYX

Pyxus

$16.40

2.98 (22.21%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Pyxus rises 23.0% »

Pyxus is up 23.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$163.99

34.34 (26.49%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Allergan rises 26.6% »

Allergan is up 26.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

, AMRN

Amarin

$18.55

0.12 (0.65%)

11:59
06/25/19
06/25
11:59
06/25/19
11:59
Periodicals
Acasti Pharma mentioned positively by Seeking Alpha contributor »

Seeking Alpha contributor…

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

AMRN

Amarin

$18.55

0.12 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Sep

AMAT

Applied Materials

$42.33

(0.00%)

11:55
06/25/19
06/25
11:55
06/25/19
11:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

ACER

Acer Therapeutics

$4.34

-14.83 (-77.36%)

11:52
06/25/19
06/25
11:52
06/25/19
11:52
Downgrade
Acer Therapeutics rating change at Raymond James »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.